ATARA Biotherapeutics (ATRA) Tops Q3 EPS by 4c

ATARA Biotherapeutics (NASDAQ: ATRA) reported Q3 EPS of ($0.90), $0.04 better than the analyst estimate of ($0.94). Revenue for the quarter came in at $5.4 million versus the consensus estimate of $3.92 million.

For earnings history and earnings-related data on ATARA Biotherapeutics (ATRA) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• PagerDuty, Inc. (PD) Tops Q2 EPS by 1c; offers guidance
• Benchmark Reiterates Buy Rating on Marvell (MRVL) Following Earnings